CD4 and non-small cell lung carcinoma: We have recently reported that SBRT can induce a significant decrease in the mean absolute counts of CD8 + cytotoxic T lymphocytes (CTLs) and CD4 + T-cells in early-stage non-small cell lung cancer (NSCLC) patients10.